NASDAQ:PODD - Insulet Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $266.43
Forecasted Upside: -5.67 %
Number of Analysts: 15
Breakdown:
0 Sell Ratings
8 Hold Ratings
7 Buy Ratings
0 Strong Buy Ratings

^$282.45 As of 06/11/2021 01:00 AM ET

▲ +0.85 (0.30%)

1 month | 3 months | 12 months

Get New Insulet Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for PODD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PODD

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$266.43

▼ -5.67% Downside Potential

This price target is based on 15 analysts offering 12 month price targets for Insulet in the last 3 months. The average price target is $266.43, with a high forecast of $300.00 and a low forecast of $230.00. The average price target represents a -5.67% upside from the last price of $282.45.

Hold

The current consensus among 15 contributing investment analysts is to hold stock in Insulet. This rating has held steady since March 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
8 buy ratings
7 hold ratings
1 sell ratings

Ratings as of

12/21/2019

0 strong buy ratings
10 buy ratings
7 hold ratings
1 sell ratings

Ratings as of

3/20/2020

0 strong buy ratings
10 buy ratings
8 hold ratings
1 sell ratings

Ratings as of

6/18/2020

0 strong buy ratings
9 buy ratings
10 hold ratings
1 sell ratings

Ratings as of

9/16/2020

0 strong buy ratings
8 buy ratings
9 hold ratings
1 sell ratings

Ratings as of

12/15/2020

0 strong buy ratings
7 buy ratings
11 hold ratings
1 sell ratings

Ratings as of

3/15/2021

0 strong buy ratings
6 buy ratings
8 hold ratings
0 sell ratings

Ratings as of

5/14/2021

0 strong buy ratings
7 buy ratings
8 hold ratings
0 sell ratings

Ratings as of

6/13/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
5/24/2021	Barclays	Initiated Coverage	Overweight	$300.00	Low	i
5/7/2021	Raymond James	Lower Price Target	Outperform	$296.00 ➝ $285.00	High	i
5/7/2021	SVB Leerink	Lower Price Target	Outperform	$320.00 ➝ $300.00	High	i Rating by D. Antalffy at SVB Leerink LLC
5/7/2021	Piper Sandler	Lower Price Target	Neutral	$260.00 ➝ $250.00	High	i
5/7/2021	BTIG Research	Reiterated Rating	Hold		High	i
4/1/2021	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$275.00 ➝ $320.00	Low	i Rating by D. Antalffy at SVB Leerink LLC
3/19/2021	Canaccord Genuity	Upgrade	Hold ➝ Buy	$280.00	High	i
3/2/2021	SVB Leerink	Boost Price Target	Market Perform	$255.00 ➝ $275.00	Low	i
2/25/2021	Oppenheimer	Boost Price Target	Market Perform	$235.00 ➝ $277.00	High	i
2/24/2021	SVB Leerink	Reiterated Rating	Market Perform	$255.00 ➝ $275.00	High	i
2/24/2021	Raymond James	Boost Price Target	Outperform	$282.00 ➝ $296.00	Low	i
2/1/2021	BTIG Research	Reiterated Rating	Hold		Low	i
1/29/2021	Piper Sandler	Downgrade	Overweight ➝ Neutral	$260.00	Medium	i
1/15/2021	Wells Fargo & Company	Reiterated Rating	Buy		Medium	i
12/16/2020	Smith Barney Citigroup	Downgrade	Buy ➝ Neutral	$255.00 ➝ $268.00	Medium	i
12/16/2020	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Downgrade	Buy ➝ Neutral	$255.00 ➝ $268.00	Medium	i
12/15/2020	Morgan Stanley	Boost Price Target	Equal Weight	$246.00 ➝ $276.00	Low	i
11/5/2020	Canaccord Genuity	Boost Price Target	Hold	$210.00 ➝ $240.00	High	i
11/5/2020	UBS Group	Boost Price Target	Neutral	$230.00 ➝ $245.00	Medium	i
11/5/2020	Wells Fargo & Company	Boost Price Target	Overweight	$250.00 ➝ $266.00	High	i
11/5/2020	Raymond James	Boost Price Target	Outperform	$249.00 ➝ $250.00	High	i
11/5/2020	Morgan Stanley	Boost Price Target	Equal Weight	$232.00 ➝ $246.00	High	i
10/12/2020	SVB Leerink	Boost Price Target	Market Perform	$240.00 ➝ $255.00	Low	i Rating by D. Antalffy at SVB Leerink LLC
8/7/2020	Morgan Stanley	Boost Price Target	Equal Weight	$222.00 ➝ $232.00	High	i
8/7/2020	Oppenheimer	Reiterated Rating	Hold	$235.00	Medium	i
8/7/2020	Stephens	Boost Price Target	Positive ➝ Equal Weight	$165.00 ➝ $230.00	Medium	i
8/7/2020	SVB Leerink	Boost Price Target	Market Perform	$215.00 ➝ $240.00	Medium	i Rating by D. Antalffy at SVB Leerink LLC
8/7/2020	Raymond James	Boost Price Target	Outperform	$200.00 ➝ $249.00	Medium	i
8/7/2020	Citigroup	Boost Price Target	Buy	$200.00 ➝ $255.00	Medium	i
8/6/2020	Piper Sandler	Reiterated Rating	Overweight	$235.00 ➝ $260.00	Medium	i Rating by Matthew O'Brien at Piper Sandler
7/28/2020	Wells Fargo & Company	Initiated Coverage	Overweight	$231.00	High	i
7/7/2020	Cowen	Boost Price Target	Positive ➝ Outperform	$220.00 ➝ $230.00	Low	i Rating by Ryan Blicker at Cowen Inc
6/9/2020	Raymond James	Lower Price Target	Outperform	$220.00 ➝ $200.00	Low	i
5/8/2020	Cfra	Boost Price Target	Sell	$162.00 ➝ $179.00	Low	i
5/8/2020	UBS Group	Boost Price Target	Neutral	$195.00 ➝ $213.00	High	i
5/8/2020	Stifel Nicolaus	Boost Price Target	Hold	$161.00 ➝ $195.00	High	i
5/8/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	$200.00 ➝ $235.00	High	i
5/8/2020	Robert W. Baird	Boost Price Target		$189.00 ➝ $242.00	High	i
5/8/2020	Morgan Stanley	Boost Price Target	Equal Weight	$186.00 ➝ $222.00	Medium	i
5/8/2020	SVB Leerink	Boost Price Target	Market Perform	$200.00 ➝ $230.00	High	i Rating by D. Antalffy at SVB Leerink LLC
5/8/2020	Citigroup	Boost Price Target	Buy	$206.00 ➝ $250.00	High	i
4/27/2020	Raymond James	Boost Price Target	Outperform	$205.00 ➝ $220.00	Medium	i
4/24/2020	SVB Leerink	Downgrade	Outperform ➝ Market Perform		Low	i Rating by D. Antalffy at SVB Leerink LLC
4/3/2020	Bank of America	Initiated Coverage	Neutral	$200.00	Medium	i
3/31/2020	Berenberg Bank	Downgrade	Buy ➝ Hold		High	i
3/27/2020	Morgan Stanley	Boost Price Target	Equal Weight	$181.00 ➝ $186.00	Low	i
3/27/2020	Citigroup	Lower Price Target	Buy	$220.00 ➝ $206.00	Medium	i
3/4/2020	Citigroup	Initiated Coverage	Buy	$220.00	Low	i
2/26/2020	Piper Sandler	Reiterated Rating	Buy	$200.00	High	i Rating by Matthew O'Brien at Piper Sandler
2/26/2020	Cowen	Reiterated Rating	Buy		High	i Rating by Ryan Blicker at Cowen Inc
2/26/2020	Cfra	Lower Price Target	Sell	$163.00 ➝ $162.00	Low	i
2/26/2020	Robert W. Baird	Lower Price Target	Outperform	$225.00 ➝ $215.00	High	i
2/26/2020	BTIG Research	Reiterated Rating	Hold		High	i
2/26/2020	Raymond James	Lower Price Target	Outperform	$213.00 ➝ $205.00	High	i
2/6/2020	Raymond James	Boost Price Target	Outperform	$158.00 ➝ $213.00	Medium	i
12/20/2019	JPMorgan Chase & Co.	Boost Price Target	Overweight	$170.00 ➝ $200.00	Medium	i
12/17/2019	Morgan Stanley	Boost Price Target	Equal Weight	$148.00 ➝ $181.00	Low	i
12/10/2019	Cfra	Initiated Coverage	Sell	$163.00	Medium	i
12/9/2019	Canaccord Genuity	Boost Price Target	Hold	$150.00 ➝ $165.00	Low	i Rating by Kyle Rose at Canaccord Genuity
11/18/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$170.00 ➝ $200.00	Low	i Rating by JP McKim at Piper Jaffray Companies
11/6/2019	Raymond James	Boost Price Target	Outperform	$135.00 ➝ $158.00	High	i
11/6/2019	Piper Jaffray Companies	Reiterated Rating	Overweight	$160.00 ➝ $170.00	High	i Rating by JP McKim at Piper Jaffray Companies
10/22/2019	Stifel Nicolaus	Initiated Coverage	Hold	$163.00	High	i
10/21/2019	Cowen	Set Price Target	Buy	$165.00	Medium	i Rating by Ryan Blicker at Cowen Inc
10/18/2019	Canaccord Genuity	Downgrade	Buy ➝ Hold	$135.00 ➝ $145.00	Medium	i
10/14/2019	BTIG Research	Downgrade	Buy ➝ Neutral		Medium	i
10/4/2019	UBS Group	Downgrade	Buy ➝ Neutral	$155.00 ➝ $160.00	Low	i
10/3/2019	Guggenheim	Downgrade	Buy ➝ Neutral		Medium	i
9/24/2019	SVB Leerink	Boost Price Target	Outperform	$160.00 ➝ $185.00	High	i Rating by D. Antalffy at SVB Leerink LLC
9/23/2019	Piper Jaffray Companies	Reiterated Rating	Buy		Low	i Rating by JP McKim at Piper Jaffray Companies
8/6/2019	Morgan Stanley	Boost Price Target	Equal Weight	$127.00 ➝ $135.00	High	i
8/6/2019	BTIG Research	Boost Price Target	Buy	$140.00	High	i
8/6/2019	BMO Capital Markets	Boost Price Target	Outperform	$130.00 ➝ $150.00	High	i
8/6/2019	Jefferies Financial Group	Boost Price Target	Buy	$105.00 ➝ $140.00	High	i
8/6/2019	Raymond James	Boost Price Target	Outperform	$125.00 ➝ $135.00	High	i
8/6/2019	Guggenheim	Boost Price Target	Buy ➝ Positive	$100.00 ➝ $145.00	High	i
8/6/2019	Canaccord Genuity	Boost Price Target	Buy	$110.00 ➝ $135.00	High	i
8/6/2019	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$120.00 ➝ $155.00	High	i
8/6/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$130.00 ➝ $160.00	High	i
7/16/2019	Morgan Stanley	Boost Price Target	Equal Weight	$98.00 ➝ $127.00	Low	i
7/10/2019	SVB Leerink	Reiterated Rating	Outperform		Low	i Rating by D. Antalffy at SVB Leerink LLC
6/28/2019	Piper Jaffray Companies	Boost Price Target	Overweight ➝ Positive	$110.00 ➝ $130.00	High	i
6/27/2019	JPMorgan Chase & Co.	Boost Price Target	Neutral	$90.00 ➝ $120.00	Low	i
6/13/2019	UBS Group	Boost Price Target	Buy	$110.00 ➝ $130.00	Low	i
6/10/2019	Northland Securities	Downgrade	Outperform ➝ Market Perform	$100.00	Low	i
5/6/2019	Canaccord Genuity	Reiterated Rating	Buy	$100.00 ➝ $110.00	High	i
5/6/2019	BTIG Research	Upgrade	Neutral ➝ Buy	$115.00	High	i
2/26/2019	Oppenheimer	Set Price Target	Hold	$100.00	Medium	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
2/26/2019	Northland Securities	Reiterated Rating	Buy	$100.00	High	i
2/19/2019	Canaccord Genuity	Boost Price Target	Buy	$90.00 ➝ $100.00	Medium	i
1/3/2019	SVB Leerink	Reiterated Rating	Outperform	$110.00 ➝ $100.00	Medium	i
1/2/2019	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$105.00 ➝ $90.00	High	i
11/27/2018	UBS Group	Initiated Coverage	Buy	$105.00	Medium	i
11/2/2018	Oppenheimer	Set Price Target	Hold	$100.00	High	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
10/11/2018	Morgan Stanley	Boost Price Target	Equal Weight	$96.00 ➝ $105.00	Medium	i
9/11/2018	SVB Leerink	Reiterated Rating	Outperform	$130.00	Medium	i
8/3/2018	Jefferies Financial Group	Reiterated Rating	Buy	$97.00	Low	i
8/3/2018	Oppenheimer	Set Price Target	Hold	$96.00	High	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
7/10/2018	BMO Capital Markets	Boost Price Target	Top Pick	$115.00	Medium	i
6/4/2018	Piper Jaffray Companies	Boost Price Target	Overweight	$106.00	Low	i
6/1/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$87.00 ➝ $96.00	Low	i
5/23/2018	Canaccord Genuity	Boost Price Target	Buy ➝ Buy	$96.00 ➝ $100.00	Low	i
5/4/2018	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$90.00 ➝ $100.00	High	i
5/4/2018	Northland Securities	Reiterated Rating	Buy	$100.00	Low	i
5/4/2018	Oppenheimer	Set Price Target	Hold	$90.00	High	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
5/3/2018	Piper Jaffray Companies	Boost Price Target	Overweight	$88.00 ➝ $90.00	High	i
5/2/2018	Canaccord Genuity	Reiterated Rating	Buy	$90.00	Medium	i
4/20/2018	Berenberg Bank	Initiated Coverage	Buy	$100.00	Medium	i
4/3/2018	Guggenheim	Initiated Coverage	Buy	$105.00	Low	i
3/5/2018	BMO Capital Markets	Initiated Coverage	Outperform	$90.00	High	i
2/23/2018	Jefferies Financial Group	Reiterated Rating	Buy	$90.00	Low	i
2/23/2018	Canaccord Genuity	Boost Price Target	Neutral	$78.00 ➝ $88.00	Low	i
2/22/2018	Cowen	Reiterated Rating	Outperform ➝ Outperform	$80.00 ➝ $90.00	Medium	i
2/22/2018	Oppenheimer	Set Price Target	Hold	$82.00	High	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
2/22/2018	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$76.00 ➝ $87.00	High	i
2/22/2018	Stephens	Reiterated Rating	Equal Weight ➝ Equal Weight	$60.00 ➝ $81.00	High	i
2/22/2018	Barclays	Reiterated Rating	Overweight ➝ Overweight	$85.00 ➝ $90.00	High	i
1/8/2018	Raymond James	Upgrade	Market Perform ➝ Outperform	$80.00	High	i
1/8/2018	UBS Group	Upgrade	Market Perform ➝ Outperform		High	i
12/13/2017	Barclays	Reiterated Rating	Buy	$78.00	Low	i
11/20/2017	Barclays	Boost Price Target	Overweight	$70.00 ➝ $75.00	N/A	i
11/3/2017	Morgan Stanley	Boost Price Target	Equal Weight	$55.00 ➝ $63.00	N/A	i
11/3/2017	Jefferies Financial Group	Boost Price Target	Buy	$58.00 ➝ $67.00	N/A	i
11/3/2017	Robert W. Baird	Boost Price Target	Outperform	$65.00 ➝ $72.00	N/A	i Rating by Jeff Johnson at Robert W. Baird
11/1/2017	Canaccord Genuity	Upgrade	Hold ➝ Buy	$50.00 ➝ $65.00	N/A	i
10/13/2017	Robert W. Baird	Set Price Target	Buy	$65.00	N/A	i
10/12/2017	SVB Leerink	Reiterated Rating	Outperform	$65.00 ➝ $74.00	N/A	i
10/10/2017	Wedbush	Reiterated Rating	Buy	$60.00 ➝ $65.00	N/A	i
9/27/2017	Canaccord Genuity	Reiterated Rating	Hold	$50.00	Medium	i
9/15/2017	Barclays	Initiated Coverage	Overweight ➝ Overweight	$65.00	Low	i
8/9/2017	Jefferies Financial Group	Reiterated Rating	Buy	$48.00 ➝ $58.00	Low	i
8/4/2017	Oppenheimer	Set Price Target	Hold	$55.00	Low	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
8/4/2017	Northland Securities	Reiterated Rating	Buy		Low	i Rating by Suraj Kalia at Northland Securities
8/4/2017	Cowen	Reiterated Rating	Outperform	$52.00 ➝ $63.00	High	i
7/22/2017	Oppenheimer	Reiterated Rating	Hold		High	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
7/17/2017	BTIG Research	Downgrade	Buy ➝ Neutral		Medium	i
7/14/2017	Cowen	Reiterated Rating	Buy	$52.00	Medium	i
7/14/2017	Jefferies Financial Group	Reiterated Rating	Buy	$48.00	Low	i
7/11/2017	Canaccord Genuity	Reiterated Rating	Hold	$42.00 ➝ $50.00	Low	i Rating by Kyle Rose at Canaccord Genuity
6/16/2017	Jefferies Financial Group	Reiterated Rating	Buy		Low	i
5/26/2017	Canaccord Genuity	Reiterated Rating	Hold	$42.00	Low	i Rating by Kyle Rose at Canaccord Genuity
5/25/2017	William Blair	Reiterated Rating	Outperform ➝ Outperform		Low	i Rating by M. Kaczor at William Blair
5/22/2017	Piper Jaffray Companies	Reiterated Rating	Overweight ➝ Overweight	$47.00	Low	i
5/14/2017	B. Riley	Reiterated Rating	Neutral	$44.00	Low	i
5/10/2017	Jefferies Financial Group	Lower Price Target	Buy	$53.00 ➝ $48.00	Medium	i
5/10/2017	BTIG Research	Upgrade	Neutral ➝ Buy	$47.00	Medium	i
5/9/2017	B. Riley	Reiterated Rating	Neutral	$44.00	High	i
5/9/2017	Oppenheimer	Set Price Target	Hold	$46.00	High	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
5/9/2017	Northland Securities	Reiterated Rating	Buy	$50.00	High	i
4/13/2017	Jefferies Financial Group	Reiterated Rating	Buy	$53.00	Low	i
3/6/2017	B. Riley	Reiterated Rating	Neutral	$44.00	N/A	i
3/6/2017	BTIG Research	Downgrade	Buy ➝ Neutral		N/A	i
3/1/2017	B. Riley	Reiterated Rating	Neutral	$44.00	N/A	i
2/28/2017	Oppenheimer	Set Price Target	Hold	$46.00	N/A	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
2/28/2017	Jefferies Financial Group	Boost Price Target	Buy	$45.00 ➝ $53.00	N/A	i
2/28/2017	Wedbush	Boost Price Target	Outperform ➝ Outperform	$48.00 ➝ $50.00	N/A	i
2/27/2017	Feltl & Co.	Downgrade	Buy ➝ Hold		N/A	i Rating by B. Haynor at Feltl & Co.
2/13/2017	Canaccord Genuity	Reiterated Rating	Hold	$39.00	N/A	i Rating by Kyle Rose at Canaccord Genuity
1/23/2017	Canaccord Genuity	Set Price Target	Hold	$39.00	N/A	i Rating by Kyle Rose at Canaccord Genuity
1/8/2017	BTIG Research	Reiterated Rating	Buy	$42.00	N/A	i Rating by Sean Lavin at BTIG Research
1/6/2017	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$39.00 ➝ $47.00	N/A	i
11/17/2016	JPMorgan Chase & Co.	Reiterated Rating	Hold	$38.00	N/A	i
11/17/2016	Wedbush	Reiterated Rating	Outperform	$48.00	N/A	i
11/9/2016	B. Riley	Reiterated Rating	Neutral	$40.00	N/A	i
11/7/2016	SVB Leerink	Reiterated Rating	Outperform	$55.00 ➝ $50.00	N/A	i
11/6/2016	Canaccord Genuity	Set Price Target	Hold	$39.00	N/A	i Rating by Kyle Rose at Canaccord Genuity
11/4/2016	B. Riley	Reiterated Rating	Neutral	$40.00	N/A	i
11/4/2016	JPMorgan Chase & Co.	Reiterated Rating	Hold	$38.00	N/A	i
11/4/2016	BTIG Research	Upgrade	Neutral ➝ Buy	$42.00	N/A	i Rating by Sean Lavin at BTIG Research
10/2/2016	B. Riley	Initiated Coverage	Neutral	$46.00	N/A	i
9/26/2016	B. Riley	Initiated Coverage	Neutral	$46.00	N/A	i Rating by G. Chodaczek at B. Riley
8/17/2016	JPMorgan Chase & Co.	Reiterated Rating	Hold	$38.00	N/A	i
8/16/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$52.00	N/A	i Rating by Brooks West at Piper Jaffray Companies
8/5/2016	Canaccord Genuity	Reiterated Rating	Hold	$36.00	N/A	i Rating by Kyle Rose at Canaccord Genuity
8/4/2016	SVB Leerink	Reiterated Rating	Outperform	$40.00 ➝ $50.00	N/A	i
8/4/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$41.00 ➝ $46.00	N/A	i Rating by Brooks West at Piper Jaffray Companies
8/4/2016	Jefferies Financial Group	Boost Price Target	Buy	$41.00 ➝ $45.00	N/A	i
8/4/2016	Wedbush	Boost Price Target	Outperform	$44.00 ➝ $48.00	N/A	i
7/20/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$41.00	N/A	i Rating by Brooks West at Piper Jaffray Companies
7/20/2016	Wedbush	Reiterated Rating	Outperform	$44.00	N/A	i
7/12/2016	BTIG Research	Initiated Coverage	Neutral		N/A	i
6/22/2016	Wedbush	Reiterated Rating	Outperform	$44.00	N/A	i Rating by Tao Levy at Wedbush
6/15/2016	Wedbush	Reiterated Rating	Outperform	$44.00	N/A	i Rating by Tao Levy at Wedbush

(Data available from 6/14/2016 forward)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.

Today's Range

Now: $282.45

$279.00

$282.61

50 Day Range

MA: $269.65

$225.52

$304.06

52 Week Range

Now: $282.45

$175.35

$306.46

Volume

518,800 shs

Average Volume

523,141 shs

Market Capitalization

$18.72 billion

P/E Ratio

2,172.69

Dividend Yield

N/A

Beta

0.68

Frequently Asked Questions

What sell-side analysts currently cover shares of Insulet?

The following Wall Street sell-side analysts have issued reports on Insulet in the last year: Barclays PLC, BTIG Research, Canaccord Genuity, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cowen Inc, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Smith Barney Citigroup, Stephens, SVB Leerink LLC, TheStreet, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for PODD.

What is the current price target for Insulet?

14 Wall Street analysts have set twelve-month price targets for Insulet in the last year. Their average twelve-month price target is $266.43, suggesting a possible downside of 5.7%. Barclays PLC has the highest price target set, predicting PODD will reach $300.00 in the next twelve months. Stephens has the lowest price target set, forecasting a price of $230.00 for Insulet in the next year.
View the latest price targets for PODD.

What is the current consensus analyst rating for Insulet?

Insulet currently has 8 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PODD, but not buy more shares or sell existing shares.
View the latest ratings for PODD.

What other companies compete with Insulet?

Other companies that are similar to Insulet include Abbott Laboratories, Medtronic, Intuitive Surgical, Stryker, Becton, Dickinson and, Edwards Lifesciences, Boston Scientific, IDEXX Laboratories, Baxter International, DexCom, ResMed, Teleflex, STERIS, Hologic and Abiomed.

How do I contact Insulet's investor relations team?

Insulet's physical mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier's listed phone number is 978-600-7000 and its investor relations email address is [email protected] The official website for Insulet is www.insulet.com.